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Abstract
Background Breast cancer molecular prognostic tools that
predict recurrence risk have mainly been established on
endocrine-treated patients and thus are not optimal for the
evaluation of benefit from endocrine therapy. The Stock-
holm tamoxifen (STO-3) trial which randomized post-
menopausal node-negative patients to 2-year tamoxifen
(followed by an optional randomization for an additional
3-year tamoxifen vs nil), versus no adjuvant treatment,
provides a unique opportunity to evaluate long-term
20-year benefit of endocrine therapy within prognostic risk
classes of the 70-gene prognosis signature that was
developed on adjuvantly untreated patients.
Methods We assessed by Kaplan–Meier analysis 20-year
breast cancer-specific survival (BCSS) and 10-year distant
metastasis-free survival (DMFS) for 538 estrogen receptor
(ER)-positive, STO-3 trial patients with retrospectively
ascertained 70-gene prognosis classification. Multivariable
analysis of long-term (20 years) BCSS by STO-3 trial arm
in the 70-gene high-risk and low-risk subgroups was per-
formed using Cox proportional hazard modeling adjusting
for classical patient and tumor characteristics.
Results Tamoxifen-treated, 70-gene low- and high-risk
patients had 20-year BCSS of 90 and 83%, as compared to
80 and 65% for untreated patients, respectively (log-rank
p\ 0.0001). Notably, there is equivalent tamoxifen benefit
in both high (HR 0.42 (0.21–0.86), p = 0.018) and low
(HR 0.46 (0.25–0.85), p = 0.013) 70-gene risk categories
even after adjusting for clinico-pathological factors for
BCSS. Limited tamoxifen exposure as given in the STO-3
trial provides persistent benefit for 10–15 years after
diagnosis in a time-varying analysis. 10-year DMFS was
93 and 85% for low- and high-risk tamoxifen-treated,
versus 83 and 70% for low- and high-risk untreated
patients, respectively (log-rank p\ 0.0001).
Conclusions Patients with ER-positive breast cancer,
regardless of high or low 70-gene risk classification,
receive significant survival benefit lasting over 10 years
from adjuvant tamoxifen therapy, even when given for a
relatively short duration.
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Introduction
Breast cancer is a diverse disease both in the sense of the
metastatic potential of the primary tumor as well as time
for metastasis to occur. The biological factors influencing
the long-term risk of fatal breast cancer are unknown. It is,
however, known that patients with newly diagnosed hor-
mone receptor (HR)-positive breast cancer (ER- and/or
progesterone (PR)-positive disease) have a continuous
long-term risk for fatal breast cancer progression relative to
stage-matched patients with newly diagnosed HR-negative
cancer [1]. Endocrine therapy remains the cornerstone in
management of HR-positive breast cancer since adjuvant
use of either tamoxifen or aromatase inhibitors signifi-
cantly improves the long-term survival of patients with
either localized or regional HR-positive breast cancer
[2, 3]. Survival benefit of adjuvant endocrine therapy has
been shown to be independent of patient age, menopausal
status, quantitative ER expression, nodal status, tumor size,
grade, and proliferation rate [3, 4], and almost all newly
diagnosed HR-positive breast cancers are nowadays treated
with endocrine therapy. Nonetheless, this survival benefit
varies markedly among similarly staged patients since up
to half of all HR-positive patients receive little or no
benefit from adjuvant endocrine therapy [3, 5], presumably
due to breast cancer inter-tumor heterogeneity associated
with endocrine resistance.
Gene expression signatures have helped us understand
the inter-tumor heterogeneity between breast cancer tumors
[6, 7], separating tumors into subgroups with different
underlying biology, prognosis, and treatment benefit
[8–10]. Unlike many other gene expression signatures, the
70-gene prognosis signature was developed on a systemi-
cally untreated patient cohort [11], which makes the sig-
nature suitable to evaluate treatment benefit.
Given the pressing need to understand more about long-
term breast cancer survival and endocrine therapy benefit,
we evaluated long-term endocrine therapy benefit in
women with 70-gene low- and high-risk prognosis signa-
tures using a large Swedish clinical trial (STO-3) having
complete long-term (20 years) follow-up of patients ran-
domized to receive adjuvant tamoxifen versus not.
Methods
The Stockholm tamoxifen (STO-3) trial
The Stockholm Tamoxifen (STO-3) trial enrolled post-
menopausal patients with lymph node-negative breast
cancers with tumors less than or equal to 30 mm in
diameter, randomized to 2 years of adjuvant tamoxifen
(40 mg daily) versus no adjuvant treatment. Patients in the
tamoxifen arm, who were relapse free after 2 years of
tamoxifen and who re-consented, were further randomized
to 3 additional years of tamoxifen or none. From the
original randomized trial cohort, 808 patients had formalin-
fixed paraffin-embedded (FFPE) tissue blocks of primary
breast cancer tumor available for molecular analyses, and
of these, 81 patients were excluded because there was
insufficient invasive tumor present for analysis. The
remaining 727-patient subset with FFPE material available
is well balanced to the original STO-3 cohort with regard to
tumor characteristics, such as tumor size, ER status, and
treatment arm assignment [12]. All patients included in the
STO-3 randomized trial have detailed patient and clinical
information. This study followed REMARK criteria [13].
In Sweden, all residents have a unique national regis-
tration number, which enables automatic linkage of various
records of personal information from Regional and
National registers of high validity and essentially complete
coverage. Death due to breast cancer was assessed from the
Swedish National Cause-of-Death Register with a reported
accuracy of more than 96% from January 1, 1961 and
onwards [14, 15]. The information on cause of death is
from death certificates filled out by the treating physicians.
Furthermore, information on contralateral breast cancer
was assessed from the Swedish National Cancer Registry.
Cancer registration has a legal basis in Sweden, and the
Swedish Cancer Registry has a breast cancer coverage of
more than 96% in validation studies [16]. Finally, infor-
mation on distant metastasis was assessed from the
Stockholm Breast Cancer Registry, a population-based
registry held by the Regional Cancer Centre in Stockholm.
The Breast Cancer Registry carries information on all
breast cancer diagnoses in the Swedish counties of Stock-
holm and Gotland since 1976 as well as follow-up infor-
mation including local relapse and distant metastasis.
The STO-3 trial was approved by the ethical committee
at Karolinska Institutet, and participants provided oral
consent.
70-gene signature assignments
Gene expression data were independently generated using
custom-designed arrays, Agilent Technologies (CA, USA),
containing approximately 32.1K probes, representing
approximately 21.5K unique genes from FFPE breast
cancer tumor tissue. Approximately 90% (or 652 of 727
breast cancer tumors) passed the RNA quality check (ac-
cording to the diagnostic quality model) and were used in
the analysis. The 70-gene (MammaPrint) signature was
performed according to standard protocols as previously
described, including the use of 465 normalization genes
and over 250 probes for hybridization and printing quality
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control. Patient tumor samples were classified into high or
low risk by the 0.00 threshold in the MammaPrint index
(high up to and low above 0.00 index, respectively). The
subgroup of ultralow tumors is defined by MammaPrint
index[?0.355 [17–19].
ER, PR, HER2, and Ki-67 immunohistochemistry
538 of the 652 tumors available for 70-gene evaluation were
ER positive. Immunohistochemistry (IHC) was retrospec-
tively done for ER, progesterone receptor [PR], human epi-
dermal growth factor receptor 2 [HER2], and Ki-67 using
DAKO Link48 Autostainer at the University of California
Davis Medical Center (UCDMC). The antibodies used were
ER (SP1; Spring Bioscience M301), PR (PgR 636; DAKO
IR068), HER2 (HercepTest; DAKOSK001), andKi67 (MIB-
1; DAKO M7240), with EnVision ? detection, following
standard recommended procedures and with per-run positive
controls assessed by quantitative image analysis to ensure
consistent run-to-run staining intensity [19].
Tumor grade
Tumor grade according to the Nottingham system was
retrospectively assessed by one pathologist [12].
Statistical methods
Survival analyses
The outcome of interest was death due to breast cancer, and
analyses of long-term breast cancer-specific survival
(20 year) by the 70-gene risk classification (high and low
risk) were performed in patients with ER-positive tumors.
Patient follow-up started at the date of primary breast
cancer diagnosis and ended at the date of death, con-
tralateral breast cancer diagnosis, emigration from Sweden
(only five women emigrated in total), or end of study fol-
low-up (December 31, 2012).
For comparison with previous studies, we also per-
formed 10-year analysis of distant metastasis-free survival.
However, information on metastasis is less complete as
compared to information on death. In our study, approxi-
mately 2%, i.e., 14 patients out of 727 patients, died from
breast cancer but have missing information on metastasis.
In patients with ER-positive disease and available gene
expression information (538 patients) as included in this
study, 11 patients who died from breast cancer had missing
information on metastasis. For these 11 patients, date of
death was used instead of the date of metastasis.
Kaplan–Meier analyses were performed by STO-3 trial
arm and 70-gene risk classification. The significance was
assessed using the log-rank test.
Multivariable analysis by the 70-gene risk classification
was performed using Cox proportional hazard modeling
adjusting for classical patient and tumor characteristics
(age and calendar period of diagnosis, progesterone
receptor status, HER2 status, Ki-67 status, tumor grade,
and tumor size). Multivariable analysis for the ultralow
70-gene risk group by trial arm was not performed due to
low sample size.
Flexible parametric survival models were used to esti-
mate hazard ratios over time since diagnosis. Breast can-
cer-specific death rates were modeled through flexible
parametric survival models using a restricted cubic spline
function for the baseline mortality rate [20, 21]. Time-de-
pendent multivariable analysis was performed for 1-, 5-,
10-, 15-, and 20-year follow-up time points, adjusting for
the same patient and tumor characteristics as listed above.
A spline with three degrees of freedom was used to esti-
mate the hazard ratios. For the time-dependent covariate
(tamoxifen trial arm), we used a second spline function
with one degree of freedom to model the interactions
between the covariate and time. The stpm2 function in
Stata version 14.2 was used for the modeling and the
analyses [20].
The proportional hazard assumption for the main
exposure variable (70-gene risk classification) was assessed
by including a time-dependent covariate in the model. No
significant deviation was noted. Data preparation and
analysis were done using SAS version 9.4, Stata version
14.2, and R version 3.4.0.
Results
Patients in the STO trial with ER-positive breast cancer
disease and available 70-gene expression signature data,
538 patients in total, were included in our analysis. In
Table 1, patient and tumor characteristics by the 70-gene
risk classification (high versus low risk) are presented. Of
167 patients with tumors classified as being high risk (167/
538, 31%), 54% of the tumors were PR positive, 14% were
HER2 positive, 41% had Ki-67 greater than 15, and 5.5%
of tumors were grade 1. Of the 371 patients with tumors
classified as being low risk (371/538, 69%), 76% of the
tumors were PR positive, no tumors were HER2 positive,
15% had Ki-67 greater than 15, and 29% of tumors were
grade 1.
Survival analysis
Univariate survival analysis
Kaplan–Meier survival graphs for patients with and with-
out tamoxifen are shown per trial arm and by the standard
Breast Cancer Res Treat (2017) 166:593–601 595
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70-gene high- and low-risk groups in Fig. 1S. A statisti-
cally significant difference in long-term (20 year) breast
cancer-specific survival by STO-3 trial arm and 70-gene
classification was observed (log-rank p\ 0.0001). For the
70-gene low-risk group, the 20-year breast cancer-specific
survival with and without tamoxifen treatment was 90%
(95% CI 84–94%) and 80.0% (95% CI 72–86%),
respectively. For the 70-gene high-risk group, the 20-year
breast cancer-specific survival with and without tamoxifen
treatment was 83% (95% CI 72–90%) and 65% (95% CI
53–75%), respectively.
The benefit of tamoxifen within each 70-gene risk group
is shown in Fig. 1a and b, respectively. A statistically
significant difference in long-term (20 year) breast cancer-
Table 1 Patient and tumor characteristics by 70-gene risk classification
STO-3 trial
70-Gene high risk 70-Gene low risk Total number
of patients
Number Percent Number Percent
STO-3 trial arm
Tamoxifen-treated arm 82 49.1 199 53.6 281
Untreated arm 85 50.9 172 46.4 257
Patient characteristics
Calendar period of primary diagnosis
1976–1984 92 55.1 182 49.1 274
1985–1990 75 44.9 189 50.9 264
Age at primary diagnosis (years)
45–54 22 13.2 30 8.1 52
55–64 81 48.5 184 49.6 265
65–74 64 38.3 157 42.3 221
Primary tumor characteristics
Type of surgery
Breast-conserving surgery and RT 28 16.8 93 25.1 121
Mastectomy 139 83.2 278 74.9 417
Progesterone receptor status
Positive 89 53.9 278 76.4 367
Negative 76 46.1 86 23.6 162
Unknown 2 – 7 – 9
HER2 statusa
Positive 24 14.4 0 0 24
Negative 143 85.6 370 100 513
Unknown 0 – 1 – 1
Ki-67 statusb
Positive 66 41.3 51 14.5 117
Negative 94 58.7 301 85.5 395
Unknown 7 – 19 – 26
Tumor grade
1 9 5.5 107 29.2 116
2 91 55.5 247 67.5 338
3 64 39.0 12 3.3 76
Unknown 3 – 5 – 8
Tumor size
pT\ 20 mm 122 74.4 315 85.6 437
pT C 20 mm 42 25.6 53 14.4 95
Unknown 3 – 3 – 6
a HER2 positive defined as 3? by immunohistochemistry
b Ki-67 cut-off for positivity at 15%
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specific survival by STO-3 trial arm (tamoxifen-treated
versus untreated) was seen within the high- as well as the
low-risk group (70-gene high risk, tamoxifen yes/no: log-
rank p = 0.0066, 70-gene low risk, tamoxifen yes/no: log-
rank p = 0.012). The benefit of tamoxifen was further
investigated in the earlier defined ultralow-risk group of
breast cancer patients with indolent disease and extremely
good outcome [19]. No statistically significant difference in
long-term survival was seen (Fig. 2, log-rank p = 0.39) in
the ultralow-risk group for patients receiving tamoxifen
therapy or not.
In order to compare results to previous studies that
evaluated endocrine treatment benefit in prognostic high-
and low-risk subgroups up to 10 year after diagnosis, we
also performed a 10-year analysis of distant metastasis-free
survival by the 70-gene risk classification using Kaplan–
Meier analysis (four groups: low risk/treated arm, low risk/
untreated arm, high risk/treated arm, and high risk/
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Fig. 1 Kaplan–Meier analysis
of breast cancer-specific
survival by 70-gene risk
classification and trial arm
(tamoxifen treated versus
untreated). The p value is based
on the log-rank test, and
numbers at risk are shown
underneath the graph. a 70-gene
high risk by trial arm (with and
without tamoxifen). b 70-gene
low risk by trial arm (with and
without tamoxifen)
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untreated arm). A statistically significant difference in
10-year distant metastasis-free survival was seen (Fig. 2S
log-rank, p\ 0.0001). For the 70-gene low-risk group, the
10-year distant metastasis-free survival with and without
tamoxifen treatment was 93% (95% CI 88–96%) and 83%
(95% CI 76–88%), respectively. For the 70-gene high-risk
group, the 10-year distant metastasis-free survival with and
without tamoxifen treatment was 85% (95% CI 75–91%)
and 70% (95% CI 58–79%), respectively.
Multivariable survival analysis
Multivariable analysis of long-term (20 years) breast can-
cer-specific survival by STO-3 trial arm in the 70-gene
high-risk and the low-risk subgroups was performed using
Cox proportional hazard modeling adjusting for classical
patient and tumor characteristics (age and calendar period
of diagnosis, progesterone receptor status, HER2 status,
Ki-67 status, tumor grade, and tumor size). Interestingly,
both patients classified as 70-gene high, as well as low risk
notably benefited from tamoxifen treatment (Table 2) after
adjusting for clinico-pathological factors. Patients with
high-risk tumors that were in the tamoxifen trial arm had a
significantly reduced risk of dying from breast cancer,
relative risk reduction of 58%, as compared to patients in
the untreated arm [Hazard ratio (HR), 0.42; 95% CI
0.21–0.86]. Low-risk patients that were treated with
tamoxifen had a significantly reduced risk (relative risk
reduction of 54%) of dying from breast cancer [Hazard
ratio (HR), 0.46; 95% CI 0.25–0.85].
Finally, time-dependent multivariable analyses were
also performed 1, 5, 10, 15, and 20 years after breast
cancer diagnosis using flexible parametric survival models
to estimate hazard ratios. For both low- and high-risk
tumors, patients had a significant benefit of tamoxifen
treatment up to 10 years after diagnosis but less benefit
after (Table 3).
Discussion
In this study, we had the rare opportunity to observe the
long-term (20-year) impact of tamoxifen therapy versus not
as the sole adjuvant therapy in women whose tumors were
retroactively molecularly classified as either 70-gene high
or low risk. The results demonstrate that there is a signif-
icant and comparable risk reduction benefit from tamoxifen
in both groups, and that the survival benefit after 2 years of
tamoxifen use (for one-third of patients in the tamoxifen
arm after 5 years) continues for well over 10 years. These
findings also confirm what has previously been shown, that
the 70-gene classification is prognostic, and that women
with low risk versus high risk have higher survival inde-
pendent of treatment. In this study, adjuvant tamoxifen
appeared to reduce risk of death by 50%, regardless of
70-gene high- or low-risk biology.
It has been shown that breast cancer stage and grade do
not appreciably affect the proportional risk reduction ben-
efit from 5 years of adjuvant tamoxifen therapy [3]; this
study, however, represents the first comparative analysis of
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adjuvant tamoxifen’s risk reduction benefit based on a
priori molecularly defined risk categorization, specifically
the 70-gene prognosis signature low- and high-risk sub-
groups. These STO-3 outcome data also serve to remind us
about the natural history of HR-positive breast cancer and
illustrate the very long tail of death from breast cancer.
Even, those women with low-risk tumor biology continue
to have risk of death, and in fact their risk of death is higher
after 5 years and this continues for at least 20 years. For
those women with molecularly high risk (by the 70-gene
classification), their recurrence risk also persists up to
20 years, but the bulk of the risk is experienced in the first
5 or (to lesser extent) 10 years. Interestingly, the benefit of
adjuvant tamoxifen treatment shows the same proportional
reduction of risk of death over time for both low- and high-
risk groups. In contrast to this observation, for those STO-3
patients for whom we recently defined having a 70-gene
indolent/ultralow-risk disease with an extremely low
Table 2 Risk of long-term breast cancer-specific death (20 year) by 70-gene classification and trial arm in ER-positive breast cancer
STO-3 trial STO-3 trial arm Breast cancer-specific
deathsa
Breast cancer-specific
survivala
Patients included Trial arm Number HR (95% CI) p value
(v2)
70-gene High risk
Adjusting for classical patient and tumor
characteristics£
Treated armb 82 12 0.42
(0.21–0.86)
0.018
(5.62)
Untreated
arm
85 26 1.0 ref.
70-gene Low risk
Adjusting for classical patient and tumor
characteristics£
Treated armb 199 17 0.46
(0.25–0.85)
0.013
(6.15)
Untreated
arm
172 29 1.0 ref.
Hazard rates in bold indicate statistically significant values
a 20-year breast cancer-specific survival
b Modeled by multivariable proportional hazard (Cox) analyses adjusting for age and calendar period of diagnosis, progesterone receptor status,
HER2 status, Ki-67 status, tumor grade, and tumor size
Table 3 Time-varying analysis of the long-term risk for breast cancer-specific death (20 years) by 70-gene classification and trial arm in ER-
positive breast cancer
STO-3 trial STO-3 trial arm Breast cancer-specific deathsa Years since diagnosis HR (95% CI)
Patients included Trial arm Number
70-gene High riskb Treated arm 82 12 1 0.20 (0.05–0.74)
5 0.37 (0.21–0.67)
10 0.55 (0.33–0.90)
15 0.81 (0.33–1.99)
20 1.00 (0.31–3.28)
Untreated arm 85 26 1.0 ref.
70-gene Low riskb Treated arm 199 17 1 0.20 (0.05–0.75)
5 0.37 (0.20–0.67)
10 0.53 (0.3–0.87)
15 0.75 (0.35–1.62)
20 0.90 (0.33–2.84)
Untreated arm 172 29 1.0 ref.
Hazard rates in bold indicate statistically significant values
a 20-year breast cancer-specific survival
b Modeled by flexible parametric survival analysis adjusting for age and calendar period of diagnosis, progesterone receptor status, HER2 status,
Ki-67 status, tumor grade, and tumor size
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20-year risk of death [19], we show that BCSS benefit from
adjuvant tamoxifen does not achieve clinical significance
over a period of 20 years relative to untreated patients with
ultralow-risk ER-positive breast cancer.
Most prognostic tools have been shown to determine
risk of recurrence only out to 10 years in a uniformly
endocrine-treated population, making these tools less
suitable to evaluate their ability to identify which patients
might and to what extent benefit from endocrine therapy
[3]. This is the first time a prognostic tool shows a benefit
of tamoxifen as the sole adjuvant therapy for molecularly
identified high-risk patients, alongside the benefit in low-
risk patients. The reason that the 70-gene signature is able
to identify this benefit across all risk groups is based on the
fact that the signature was developed in an adjuvant
treatment-naı¨ve population, whereas other prognosis sig-
natures like Oncotype and Endopredict have been devel-
oped on tamoxifen-treated population [9, 22]. The benefit
of tamoxifen is therefore difficult to discern [9]. Our
analysis of distant metastasis-free survival at 10 years also
allows direct comparison with previously published papers
for patients having received endocrine treatment which
results in comparable 10-year DMFS rates [9, 22, 23].
Interestingly, this paper also likely confirms the additive
benefit of chemotherapy, as risk for recurrence is more
substantial in the first 5 years in the high-risk group as
compared to the low-risk group. Even if the relative benefit
of tamoxifen risk reduction is the same, the absolute risk of
recurrence is higher in the high-risk group, where
chemotherapy is known to exert its optimal effect [24]. In the
low-risk and particularly the ultralow-risk group, the abso-
lute risk of recurrence is extremely low in the first 5 years,
therefore making it unlikely that there would be benefit from
chemotherapy, an observation recently made in the large
prospective randomized MINDACT trial for breast cancers
with 70-gene low-risk signature even within the clinical
high-risk setting [10, 25].
In order to advance the science of personalized medi-
cine, diagnostics need to help us determine who will ben-
efit and when. Women with ultralow-risk profiles have
almost no risk and therefore benefit little if at all even from
endocrine treatment. Women with biologically high-risk
disease benefit from tamoxifen, but have high early resid-
ual risk supporting a decision to intercede with
chemotherapy. Women with low- but not ultralow-risk
disease, as well as those with high-risk disease, would be
very well served if we had a robust marker of sensitivity to
endocrine therapy and chemotherapy, to understand their
long-term risk to die from breast cancer. That way, we
could find ways to intercede for this group of women, and,
as well, to determine for whom endocrine therapy is not
sufficient. In order to more rapidly advance the field, we
have to be able to identify those women at diagnosis and
specifically focus more targeted interventions. Establishing
the long-term benefit of endocrine therapy in prognostic
subclasses as described here contributes to our ability to
guide the use of adjuvant therapy in breast cancer.
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